Efficacy and Safety Study of Dupilumab in Patients With Persistent Asthma

  • STATUS
    Recruiting
  • End date
    Sep 4, 2022
  • participants needed
    486
  • sponsor
    Sanofi
Updated on 4 October 2020
corticosteroids
prednisone
nitric oxide
bronchodilator
fractional exhaled nitric oxide
persistent asthma
eosinophil count

Summary

Primary Objective:

To evaluate the efficacy of dupilumab in patients with persistent asthma

Secondary Objectives:

  • To evaluate the safety and tolerability of dupilumab
  • To evaluate the effect of dupilumab on improving patient reported outcomes including health related quality of life
  • To evaluate dupilumab systemic exposure and immunogenicity

Description

The total duration of study per patient is approximately 40 weeks, including 3 to 5 weeks of screening period, 24 weeks of treatment period and 12 weeks of post-treatment period.

Details
Treatment Placebo, Asthma Reliever Therapies, Dupilumab SAR231893, Asthma Controller Therapies (include prednisone/prednisolone)
Clinical Study IdentifierNCT03782532
SponsorSanofi
Last Modified on4 October 2020

Adding a note
adding personal notes guide

Select a piece of text and start making personal notes.

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 12 yrs?
Gender: Male or Female
Do you have any of these conditions: Asthma or Asthma (Pediatric) or Allergies & Asthma?
Adults and adolescent patients (12 years of age) with a physician diagnosis of asthma for 12 months, based on the Global Initiative for Asthma 2017 Guidelines and the following criteria
Patients requiring a third controller for their asthma will be considered eligible for this study, and it should also be used for at least 3 months with a stable dose 1 month prior to the screening visit (Visit 1)
Patients requiring maintenance oral corticosteroids (OCS) with a stable dose 10 mg/day prednisone or equivalent will be allowed; OCS should be used for at least 3 months with a stable dose 1 month prior to the screening visit (Visit 1)
Pre-bronchodilator FEV1 80% of predicted normal for adults and 90% of predicted normal for adolescents at the screening visit and the randomization visit (Visits 1 and 2), prior to randomization
Asthma Control Questionnaire 5-question version (ACQ-5) score 1.5 at the screening visit and the randomization visit (Visits 1 and 2), prior to randomization
For patients not requiring maintenance OCS, screening blood eosinophil count 150 cells/L or Fractional Exhaled Nitric Oxide (FENO) 25 parts per billion (ppb); for patients requiring maintenance OCS, there is no minimum requirement for blood eosinophil count and FENO level

Exclusion Criteria

Patients <12 years of age or the minimum legal age for adolescents in the country of the investigative site, whichever is higher (for those countries where local regulations permit enrollment of adults only, patient recruitment will be restricted to those who are 18 years of age)
Weight is less than 30 kg at the screening visit (Visit 1) or the randomization visit (Visit 2)
Chronic obstructive pulmonary disease or other lung diseases (eg, idiopathic pulmonary fibrosis) which may impair lung function
A patient who experiences a severe asthma exacerbation (defined as deterioration of asthma that results in emergency treatment, hospitalization due to asthma, treatment with systemic steroids, or treatment with systemic steroid at least twice the previous dose for patients on OCS maintenance) at any time from 1 month prior to the screening visit (Visit 1) up to and including the randomization visit (Visit 2)
Evidence of lung disease(s) other than asthma, either clinical or imaging evidence (eg, chest X-ray, computed tomography, and magnetic resonance imaging) within 3 months prior to the screening visit (Visit 1) as per local standard of care
Current smoker or cessation of smoking within 6 months prior to the screening visit (Visit 1)
Previous smoker with a smoking history >10 pack-years
Comorbid disease that might interfere with the evaluation of investigational medicinal product (IMP)
The above information is not intended to contain all considerations relevant
to a patient's potential participation in a clinical trial
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.
Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more
Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more
Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study

user name

Annotated by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No made yet